The positive action continues for shares of OrganiGram Holdings Inc (OTCMKTS:OGRMF). The stock moved back above its 50-day simple moving average to close out last week, with volume in the tape showing some positive signs as well. In addition, the company just announced that it has received an expanded cultivation license from Health Canada in line with its previously announced Phase 4A and 4B expansion plans for its Moncton Campus.

The marijuana industry is looking like it could be one of the greatest growth stories of our generation. Having long existed behind the scenes in the black market, the now-legal pot industry is budding, and it has quite the audience in Wall Street.

Last year, the global legal cannabis industry generated $12.2 billion in sales -- and this is just the beginning.

Depending on your preferred Wall Street investment firm, the legal pot industry is capable of between $50 billion and $75 billion in worldwide sales by the end of next decade, and perhaps $130 billion to $166 billion in peak yearly sales (although no specific time frame was provided).

Canadians are less enthusiastic about the prospect of legalized edibles than they were in 2017, a Dalhousie University study has suggested.

Some marijuana stocks are hot. And some are not. HEXO (NYSEMKT:HEXO) definitely falls into the former category. Its shares have more than doubled so far this year. MariMed (NASDAQOTH:MRMD), on the other hand, isn't so hot in 2019. Although the stock soared 371% in 2018, MariMed is down 3% year to date. But which of these two marijuana stocks is the better long-term pick for investors? Here's what you need to know about HEXO and MariMed.

When it comes to investing in the marijuana industry, production isn't everything. But let's be clear -- it's still a really important piece of the puzzle. But what's arguably more important than simple peak production is how well cannabis growers convert their licensed square footage into yield. In other words, efficiency is king.

Pardon the cliche, but the marijuana industry appears to be the greatest thing since sliced bread.

Although the cannabis industry has existed for decades behind the scenes, the legalization of recreational weed in Canada, along with more than 40 countries giving medical marijuana the green light around the world, has opened the floodgates for legal revenue to flow into the industry.

But, as is common with any nascent and fast-growing industry, it's dealing with growing pains. This is especially true of our neighbor to the north, Canada.

With a population size of 740 million people, Europe’s population dwarfs both Canada and the U.S combined. The sizable growth the cannabis industry has had over the past 12 months can be attributed to six countries that have announced medical cannabis legalization.

So far, over €500.0M has been invested in European cannabis businesses (Prohibition Partners, 2019). It is predicted that Europe over the next five years will be the largest legal cannabis market in the world and could be worth up to €123.0B by 2028. Today we have identified four Canada-listed cannabis stocks with promising operations in the European Union (EU).

Nearly everything that could go right has done so for Canopy Growth (NYSE:CGC). On the other hand, nearly everything that could go wrong has done so for Aphria (NYSE:APHA).

The stock performances for the two Canadian marijuana producers sort of show it, with Canopy's shares more than doubling over the last 12 months and Aphria's shares sinking nearly 20% during the period.

However, the past, whether good or bad, doesn't necessarily translate to how well a company and its stock will perform in the future. Which of these two marijuana stocks is the better pick for investors now? Here's how Canopy Growth and Aphria stack up against each other.

The New Brunswick government is considering three options as it mulls the future of Cannabis NB.

Finance Minister Ernie Steeves said the options include allowing experts to run the business, scaling it down and closing the Cannabis NB stores that aren’t making money, or privatizing it.

His comments come after the province's Crown-owned cannabis retailer recorded a big financial loss in its first year of operation.

Unaudited year-end results released last week show Cannabis NB lost $11.7 million.

“It’s a real fancy model and I’ve said all along, one of the busiest businesses in Moncton is Costco. It’s a cement floor and steel shelves,” Steeves said Wednesday.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NYSE: CGC) is pleased to announce today that has signed an offtake agreement with PharmHouse Inc. (“PharmHouse”), a 49 per cent-owned joint venture of Canopy Rivers Inc. (TSXV: RIV) (OTC: CNOPOF).